Klinik für Urologie und Kinderurologie

Studien zu Erkrankungen der Niere

Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

Studien-Status: geöffnet

Weitere Informationen finden Sie hier

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Studien-Status: geöffnet

Weitere Informatioen finden Sie hier.

A National, Prospective, Non-Interventional Study (NIS) in Patients With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab And Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib

Studien-Status:

Weitere Informationen finden Sie hier.

Retrospektive Datenerhebung zu Wirksamkeit und Sicherheit von Lenvatinib+Everolimus ab der Zweitlinie bei Patienten mit fortgeschrittenem Nierenzellkarzinom.

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

T-REX: Tivozanib - Real World Experience on Tolerability, Patient Reported Outcomes and QoL in 1st line aRCC

Studien-Status: geöffnet

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date :  March 20, 2019

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

 
 
 
 

Kontakt

Barbara Thielen (Ltd. study nurse)
Ansgar Nehus (study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)

Terminvereinbarung
Telefonisch: Montag bis Freitag: 10 - 14 Uhr
unter: +49 (0)251- 83 48 12 6
Per E-Mail: uroonkologie(at)­ukmuenster(dot)­de

IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1

Dr. med. Katrin Schlack, FEBU
OA für den Bereich Uroonkologie
Prüfärztin
E-Mail: Katrin.Schlack(at)­ukmuenster(dot)­de